The period in brief – financial summary for the second quarter 2025

• Net sales amounted to SEK 0 million (SEK 0 million).
• R&D expenses amounted to SEK 4,8 million (SEK 9,7 million).
• Operating loss for the quarter amounted to SEK –6,3 million (SEK -11,4 million).
• Loss after financial items for the quarter amounted to SEK –6,3 million (SEK -10,9 million).
• Basic and diluted earnings per share for the quarter amounted to SEK –0,05 (SEK -0,09).
• Cash flow from operating activities for the quarter amounted to SEK –9,8 million (SEK -14,4 million).
• Equity on June 30, 2025 amounted to SEK 43,1 million (SEK 83,0 million) or SEK 0,36 (SEK 0,68) per share.
• The equity/assets ratio on June 30, 2025 was 92 percent (87 percent).
• Cash and cash equivalents on June 30, 2025 amounted to SEK 27,6 million (SEK 75,7 million).

Financial summary for the full period January 1- June 30, 2025

• Net sales amounted to SEK 0 million (SEK 0 million).
• R&D expenses amounted to SEK 15,8 million (SEK 21,2 million).
• Operating loss for the quarter amounted to SEK –19,5 million (SEK -24,7 million).
• Loss after financial items for the quarter amounted to SEK –19,2 million (SEK -23,9 million).
• Basic and diluted earnings per share for the period amounted to SEK –0,16 (SEK -0,22).
• Cash flow from operating activities for the period amounted to SEK –18,8 million (SEK -29,7 million).
• Equity on June 30, 2025 amounted to SEK 43,1 million (SEK 83,0 million) or SEK 0,36 (SEK 0,68) per share.
• The equity/assets ratio on June 30, 2025 was 92 percent (87 percent).
• Cash and cash equivalents on June 30, 2025 amounted to SEK 27,6 million (SEK 75,7 million).

Significant events during the second quarter 2025

• Kancera reported that the last patient has completed the last visit in the phase Ib/IIa study KANDOVA evaluating the candidate drug KAND567 in ovarian cancer.
• Kancera reported that the company has completed a successful pre-IND meeting with the FDA and received positive feedback on the planned clinical development program for KAND567 in ST-elevation myocardial infarction.
• Kancera reported positive top-line results from the KANDOVA study and that the study’s primary and secondary objectives were met.
• Kancera announced that the World Health Organization has granted rugocrixan and fosrugocrixan as the International Non-proprietary Names for the company’s candidate drugs KAND567 and KAND145.

Significant events after the end of the period

• Kancera has reported that it has terminated the letter of intent with Recardio Inc. concerning an out-licensing of the candidate drugs rugocrixan and fosrugocrixan.

About Kancera AB (publ)
Kancera is a clinical stage biotech developing a new class of small molecule drugs with an immune cell modulating mode-of-action with focus on cardiovascular diseases. The stock is traded on the Nasdaq First North Premier Growth Market. Redeye AB is the company's Certified Adviser and can be contacted at [email protected] .

For further information

• Please refer the presentation of the 2025 Q2 Interim Report, available on Kancera’s website: www.kancera.com/en/investor-relations/presentations/
• All financial reports are available at Kancera’s website: https://kancera.com/en/investor relations/financial-reports/

or contact:
[email protected] or phone: +46 (0)8-5012 60 80